No evidence of an association of multiple sclerosis (MS) with Borna disease virus 1 (BoDV-1) infections in patients within an endemic region: a retrospective pilot study.

Borna disease virus (BoDV-1) ELISA Encephalitis Multiple sclerosis (MS) Serology iIFA

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
09 Oct 2023
Historique:
received: 02 08 2023
accepted: 12 09 2023
medline: 10 10 2023
pubmed: 10 10 2023
entrez: 9 10 2023
Statut: aheadofprint

Résumé

Borna disease virus 1 (BoDV-1) causes rare human infections within endemic regions in southern and eastern Germany. The infections reported to date have been linked to severe courses of encephalitis with high mortality and mostly irreversible symptoms. Whether BoDV-1 could act as a trigger for other neurological conditions, is, however, incompletely understood. In this study, we addressed the question of whether the presentation of a clinically isolated syndrome (CIS) or of multiple sclerosis (MS) might be associated with a milder course of BoDV-1 infections. Serum samples of 100 patients with CIS or MS diagnosed at a tertiary neurological care center within an endemic region in southern Germany and of 50 control patients suffering from headache were retrospectively tested for BoDV-1 infections. In none of the tested sera, confirmed positive results of anti-BoDV-1-IgG antibodies were retrieved. Our results support the conclusion that human BoDV-1 infections primarily lead to severe encephalitis with high mortality.

Sections du résumé

BACKGROUND BACKGROUND
Borna disease virus 1 (BoDV-1) causes rare human infections within endemic regions in southern and eastern Germany. The infections reported to date have been linked to severe courses of encephalitis with high mortality and mostly irreversible symptoms. Whether BoDV-1 could act as a trigger for other neurological conditions, is, however, incompletely understood.
OBJECTIVES AND METHODS OBJECTIVE
In this study, we addressed the question of whether the presentation of a clinically isolated syndrome (CIS) or of multiple sclerosis (MS) might be associated with a milder course of BoDV-1 infections. Serum samples of 100 patients with CIS or MS diagnosed at a tertiary neurological care center within an endemic region in southern Germany and of 50 control patients suffering from headache were retrospectively tested for BoDV-1 infections.
RESULTS RESULTS
In none of the tested sera, confirmed positive results of anti-BoDV-1-IgG antibodies were retrieved. Our results support the conclusion that human BoDV-1 infections primarily lead to severe encephalitis with high mortality.

Identifiants

pubmed: 37814203
doi: 10.1007/s15010-023-02099-4
pii: 10.1007/s15010-023-02099-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : University Hospital Regensburg
ID : ReForM-A program
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : 01KI2002
Organisme : Bavarian Ministry of Health
ID : Bornavirus - Focal Point Bavaria 2.0
Organisme : Bundesministerium für Bildung und Forschung
ID : EXC 2145 SyNergy - ID 390857198
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : EXC 2145 SyNergy - ID 390857198

Informations de copyright

© 2023. The Author(s).

Références

Allartz P, Hotop S-K, Muntau B, Schlaphof A, Thomé-Bolduan C, Gabriel M, et al. Detection of bornavirus-reactive antibodies and BoDV-1 RNA only in encephalitis patients from virus endemic areas: a comparative serological and molecular sensitivity, specificity, predictive value, and disease duration correlation study. Infection. 2023;5:1–13. https://doi.org/10.1007/s15010-023-02048-1 .
doi: 10.1007/s15010-023-02048-1
Bauswein M, Eidenschink L, Knoll G, Neumann B, Angstwurm K, Zoubaa S, et al. Human infections with borna disease virus 1 (BoDV-1) primarily lead to severe encephalitis: further evidence from the seroepidemiological BoSOT study in an endemic region in Southern Germany. Viruses. 2023. https://doi.org/10.3390/v15010188 .
doi: 10.3390/v15010188 pubmed: 36680234 pmcid: 9864614
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296–301. https://doi.org/10.1126/science.abj8222 .
doi: 10.1126/science.abj8222 pubmed: 35025605
Coras R, Korn K, Kuerten S, Huttner HB, Ensser A. Severe bornavirus-encephalitis presenting as Guillain-Barré-syndrome. Acta Neuropathol. 2019;137:1017–9. https://doi.org/10.1007/s00401-019-02005-z .
doi: 10.1007/s00401-019-02005-z pubmed: 30953131
Eisermann P, Rubbenstroth D, Cadar D, Thomé-Bolduan C, Eggert P, Schlaphof A, et al. Active case finding of current bornavirus infections in human encephalitis cases of unknown etiology, Germany, 2018–2020. Emerg Infect Dis. 2021;27:1371–9. https://doi.org/10.3201/eid2705.204490 .
doi: 10.3201/eid2705.204490 pubmed: 33900167 pmcid: 8084505
Finck T, Liesche-Starnecker F, Probst M, Bette S, Ruf V, Wendl C, et al. Bornavirus encephalitis shows a characteristic magnetic resonance phenotype in humans. Ann Neurol. 2020;88:723–35. https://doi.org/10.1002/ana.25873 .
doi: 10.1002/ana.25873 pubmed: 32794235
Frank C, Wickel J, Brämer D, Matschke J, Ibe R, Gazivoda C, et al. Human Borna disease virus 1 (BoDV-1) encephalitis cases in the north and east of Germany. Emerg Microbes Infect. 2022;11:6–13. https://doi.org/10.1080/22221751.2021.2007737 .
doi: 10.1080/22221751.2021.2007737 pubmed: 34783638
Korn K, Coras R, Bobinger T, Herzog SM, Lücking H, Stöhr R, et al. Fatal encephalitis associated with borna disease virus 1. N Engl J Med. 2018;379:1375–7. https://doi.org/10.1056/NEJMc1800724 .
doi: 10.1056/NEJMc1800724 pubmed: 30281979
Neumann B, Hierl A, Wunderlich S, Meier H, Bauer C, Gerner ST, et al. Cerebrospinal fluid in Borna disease virus 1 (BoDV-1) encephalitis. J Neurol Sci. 2023. https://doi.org/10.1016/j.jns.2023.120568 .
doi: 10.1016/j.jns.2023.120568 pubmed: 36716549
Neumann B, Angstwurm K, Linker RA, Knoll G, Eidenschink L, Rubbenstroth D, et al. Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Borna disease virus 1 infections. Cell Rep Med. 2022;3:100499. https://doi.org/10.1016/j.xcrm.2021.100499 .
doi: 10.1016/j.xcrm.2021.100499 pubmed: 35106511 pmcid: 8784767
Niller HH, Angstwurm K, Rubbenstroth D, Schlottau K, Ebinger A, Giese S, et al. Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation. Lancet Infect Dis. 2020;20:467–77. https://doi.org/10.1016/S1473-3099(19)30546-8 .
doi: 10.1016/S1473-3099(19)30546-8 pubmed: 31924550
Pörtner K, Wilking H, Frank C, Böhmer MM, Stark K, Tappe D. Risk factors for Borna disease virus 1 encephalitis in Germany—a case–control study. Emerg Microbes Infect. 2023;12:e2174778. https://doi.org/10.1080/22221751.2023.2174778 .
doi: 10.1080/22221751.2023.2174778 pubmed: 36748319 pmcid: 9980402
Schlottau K, Forth L, Angstwurm K, Höper D, Zecher D, Liesche F, et al. Fatal encephalitic borna disease virus 1 in solid-organ transplant recipients. N Engl J Med. 2018;379:1377–9. https://doi.org/10.1056/NEJMc1803115 .
doi: 10.1056/NEJMc1803115 pubmed: 30281984
Tappe D, Frank C, Offergeld R, Wagner-Wiening C, Stark K, Rubbenstroth D, et al. Low prevalence of Borna disease virus 1 (BoDV-1) IgG antibodies in humans from areas endemic for animal Borna disease of Southern Germany. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-56839-4 .
doi: 10.1038/s41598-019-56839-4 pubmed: 31882942 pmcid: 6934520
Tappe D, Pörtner K, Frank C, Wilking H, Ebinger A, Herden C, et al. Investigation of fatal human Borna disease virus 1 encephalitis outside the previously known area for human cases, Brandenburg, Germany—a case report. BMC Infect Dis. 2021;21:787. https://doi.org/10.1186/s12879-021-06439-3 .
doi: 10.1186/s12879-021-06439-3 pubmed: 34376142 pmcid: 8353434

Auteurs

Markus Bauswein (M)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany. markus.bauswein@ukr.de.

Gertrud Knoll (G)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

Barbara Schmidt (B)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

André Gessner (A)

Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

Bernhard Hemmer (B)

Department of Neurology, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Martina Flaskamp (M)

Department of Neurology, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.

Classifications MeSH